DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 2003M-0045, 2003M-0122, 2003M-0010, 2003M-0040, 2003M-0086, 2003M-0116, 2003M-0049, 2003M-0070, 2003M-0011, 2003M-0046, 2003M-0114, 2003M-0115]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the agency's Division of Dockets Management.

ADDRESSES: Submit written requests for copies of summaries of safety and effectiveness to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed

in table 1 of this document when submitting a written request. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the summaries of safety and effectiveness.

FOR FURTHER INFORMATION CONTACT: Thinh Nguyen, Center for Devices and Radiological Health (HFZ–402), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2186.

SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of January 30, 1998 (63 FR 4571), FDA revised 21 CFR 814.44(d) and 814.45(d) (63 FR 4571) to discontinue individual publication of PMA approvals and denials in the Federal Register. Instead, the agency now posts this information to FDA's home page at http://www.fda.gov on the Internet. FDA believes that this procedure expedites public notification of these actions because announcements can be placed on the Internet more quickly than they can be published in the Federal Register, and FDA believes that the Internet is accessible to more people than the Federal Register.

In accordance with section 515(d)(4)and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an

order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the act. The 30-day period for requesting reconsideration of an FDA action under §10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from January 1, 2003, through March 31, 2003. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

TABLE 1.—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE JANUARY 1, 2003, THROUGH MARCH 31, 2003

PMA No./Docket No.	Applicant	Trade Name	Approval Date
P990071/03M-0045	Biosense Webster, Inc.	STOCKERT 70 RF GENERATOR FOR CARDIAC ABLATION	May 31, 2000.
P980048/03M-0122	Sulzer Spine-Tech	BAK/CERVICAL (BAK/C) INTERBODY FUSION SYSTEM	April 20, 2001.
P990065/03M-0010	Sirtex Medical, Inc.	SIR-SPHERES	March 5, 2002.
P010002/03M-0040	United States Surgical Corp.	INDERMIL TISSUE ADHESIVE	May 22, 2002.
P010041/03M-0086	Edwards Lifesciences, LLC	CARPENTIER-EDWARDS S.A.V. BIOPROSTHESIS, MODEL 2650 (AORTIC)	June 24, 2002.
P020009/03M-0116	Boston Scientific, Scimed, Inc.	EXPRESS/EXPRESS 2 MONOTRAIL AND OVER THE WIRE CORONARY STENT SYSTEMS	September 11, 2002.
P010068/03M-0049	Biosense Webster, Inc.	NAVISTAR DS/CELSIUS DS DIAGNOSTIC ABLATION CATH- ETERS, STOCKERT 70 GENERATOR, AND CATHETER INTERFACE CABLES	September 27, 2002.
P020011/03M-0070	Gen-Probe, Inc.	VERSANT HCV RNA QUALITATIVE ASSAY	November 7, 2002.
P020008/03M-0011	Karl Storz Endoscopy- America	KARL STORZ AUTOFLUORESCENCE SYSTEM	December 12, 2002.
P020027/03M-0046	Dade Behring, Inc.	DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMEN- SION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS	January 24, 2003.
P800022(S50)/03M- 0114	Inamed Corp.	COSMODERM 1 & COSMOPLAST HUMAN-BASED COLLAGEN	March 11, 2003.
P010065/03M-0115	E Med Future	NEEDLE ZAP	March 14, 2003.

II. Electronic Access

Persons with access to the Internet may obtain the documents at *http://* www.fda.gov/cdrh/pmapage.html.

Dated: October 6, 2003.

Linda S. Kahan,

Deputy Director, Center for Devices and Radiological Health. [FR Doc. 03–27119 Filed 10–27–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003N-0077]

FDA Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 008; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 28, 2003 (68 FR 22391). The document announced a publication entitled "FDA Modernization Act of 1997; Modifications to the List of Recognized Standards, Recognition List Number: 008." The publication contains modifications the agency is making to the list of standards FDA recognizes for use in the premarket reviews. The document was published with inadvertent errors. This document corrects those errors and provides clarification.

FOR FURTHER INFORMATION CONTACT:

Carol L. Herman, Center for Devices and Radiological Health (HFZ–84), Food and Drug Administration, 2094 Gaither Rd., Rockville, MD 20850, 301–594–4766, ext. 156. **SUPPLEMENTARY INFORMATION:** FDA also intended to note that it is limiting its recognition of standards 31 and 32 to the use of 25 symbols for labeling of in vitro diagnostic (IVD) devices used by professional IVD users. Elsewhere in this issue of the **Federal Register**, FDA is publishing a notice announcing the availability of a draft guidance document concerning the use of these symbols in labeling of IVDs.

In FR Doc. 03–10417, appearing on page 22391 in the **Federal Register** of Monday, April 28, 2003, the following corrections are made:

1. On page 22398, under "*B. General*", correct the table to read:

Item No.	Title of Standard	Reference No. and Date
30	Medical Electrical Equipment—Part 1–2: General Requirements for Safety—Collat- eral Standard: Electromagnetic Compatability—Requirements and Tests	ANSI/AAMI/IEC 60601–1–2:2001
31	Symbols to be Used With Medical Device La- bels, Labeling and Information to be Sup- plied	ISO 15223:2000
32	Graphical Symbols for Use in the Labeling of Medical Devices	EN 980:1996+A1:1999+A2:2001

2. On page 22399, in the first table, the entries for item nos. 30, 31, and 32 are removed.

Dated: October 2, 2003.

Linda S. Kahan,

Deputy Director, Center for Devices and Radiological Health.

[FR Doc. 03–27118 Filed 10–27–03; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2002D-0421]

Guidance for Industry and FDA Staff on Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the guidance document entitled "Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm." This guidance document describes a means by which arrhythmia detector and alarm devices may comply with the requirement of special controls for class II devices. Elsewhere in this issue of the **Federal Register**, FDA is publishing a final rule to reclassify these devices from class III into class II (special controls).

DATES: Submit written or electronic comments on agency guidances at any time.

ADDRESSES: Submit written requests for single copies on a 3.5" diskette of the guidance document entitled "Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm" to the Division of Small Manufacturers, International, and Consumer Assistance (HFZ–220), Center for Devices and Radiological Health (CDRH), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two selfaddressed adhesive labels to assist that office in processing your request, or fax your request to 301–443–8818.

Submit written comments concerning this guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http:// www.fda.gov/dockets/ecomments*. Identify comments with the docket number found in brackets in the heading of this document. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the guidance.

FOR FURTHER INFORMATION CONTACT: Elias Mallis, CDRH (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8517, ext 177.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of December 13, 2002 (67 FR 76749), FDA announced the availability of a draft of this guidance document and invited interested persons to comment on it by